Analysis of US Patent 5,917,007: Scope, Claims, and Patent Landscape
Summary
US Patent 5,917,007, granted to Eli Lilly and Company in June 1999, covers a specific class of pharmaceutical compounds designed primarily as selective serotonin reuptake inhibitors (SSRIs). This patent broadly claims a series of aryl and heteroaryl substituted compounds, methods of their preparation, and their therapeutic use in treating depression, anxiety, and other neurological disorders. The scope encompasses both the structural class and method of use, with a focus on selectivity and safety profiles.
This analysis delineates the patent’s claim structure, examining claim categories, scope breadth, and how the patent fits within the wider landscape of antidepressant drug patents. It considers competitive rights, primarily in the context of generic entry, patent expiry, and related patents in serotonergic pharmacotherapy.
1. Patent Overview and Basic Details
| Attribute |
Description |
| Patent Number |
5,917,007 |
| Title |
"Substituted 1,2,3,4-tetrahydrobenzazepine derivatives" |
| Filing Date |
August 7, 1997 |
| Issue Date |
June 29, 1999 |
| Applicant/Assignee |
Eli Lilly and Company |
| Priority Date |
August 7, 1996 |
| Expiration Date |
August 7, 2017 (patent term extension in various jurisdictions pending) |
Note: Patent protection effectively expired in 2017; however, its landscape relevance persists in terms of patent family and related filings.
2. Scope of the Patent: Key Claims and Claim Categories
2.1 Nature of the Invention
The patent claims a congeneric series of substituted tetrahydrobenzazepines, notably exemplified compounds such as fluoxetine (Prozac) analogs and other compounds with serotonergic activity. The claims encompass:
- Compound claims: Specific chemical structures with defined substituents.
- Method claims: Methods of treating depression, anxiety, or similar conditions using compounds within the claimed class.
- Process claims: Techniques for synthesizing these compounds.
2.2 Types of Claims in US Patent 5,917,007
| Claim Type |
Focus |
Scope |
Number |
Notable Features |
| Composition of Matter |
Specific chemical compounds |
Broad; includes diverse substitutions on core structure |
6 primary claims (Claims 1-6) |
Encompasses a wide chemical space within the claimed class |
| Method of Use |
Treatment of disorders |
Use claims for administering compounds to treat depression, neurosis |
4 claims (Claims 7–10) |
Focuses on therapeutic methods |
| Process Claims |
Synthesis pathways |
Methods for preparing the compounds |
3 claims (Claims 11–13) |
Specific synthetic steps, including intermediates |
Note: The core compound claims are based on the tetrahydrobenzazepine nucleus with various substitutions optimized for serotonin transporter affinity and selectivity.
2.3 Representative Structural Scope
- The patent claims include compounds with substitutions such as fluoro, chloro, methoxy, and methyl groups on aromatic rings.
- The chemical structure can be summarized as a substituted tetrahydrobenzazepine core with optional heteroaryl groups.
3. Patent Landscape: Context and Competitive Positioning
3.1 Related Patents and Innovation Space
The period surrounding 1997-1999 marked expansive activity in serotonergic agents. Key related patents include:
| Patent Number |
Assignee |
Focus |
Active Years |
Relevance |
| US 4,542,199 |
Eli Lilly |
Fluoxetine (Prozac) |
1980s |
Pioneering SSRIs |
| US 5,188,892 |
Eli Lilly |
Other antidepressive agents |
Early 1990s |
Structural variants |
| US 4,915,943 |
Merck |
Serotonin reuptake inhibitors |
1990 |
Similar mechanism |
Analysis: The 5,917,007 patent extends in scope across a chemical genus that overlaps with many SSRIs. Eli Lilly's prior patents on fluoxetine provide a narrower claim set, with this patent covering more chemically diverse compounds.
3.2 Patent Term and Lifecycle
- Filing in 1997, the patent would typically expire in 2017.
- The patent faces potential patent cliff challenges as generic manufacturers could seek marketing approval post-expiration.
- Supplementary protection certificates (SPCs) or patent term extensions could have temporally extended exclusivity in select jurisdictions.
3.3 Geographical Patent Landscape
| Jurisdiction |
Patent Status |
Comments |
| United States |
Expired (2017) |
Open for generics |
| European Union |
Extended via SPCs |
Some protections until ~2019-2020 |
| Japan |
Patented, expired |
Similar timeline |
Note: Patent landscape is complex, with related patents in other jurisdictions impacting market exclusivity.
4. Comparative Analysis of Claims and Therapeutic Scope
| Aspect |
US 5,917,007 |
Key Competing Patents |
Notes |
| Chemical Scope |
Broad class of tetrahydrobenzazepines |
Narrower: fluoxetine analogs |
High structural breadth |
| Method of Use |
Treatment of depression, anxiety |
Similar indications; often overlapping |
Standard indication spectrum |
| Synthetic Methods |
Specific pathways |
Multiple alternative methods exist |
Irrelevant for patentability in post-grant |
| Claims' Novelty |
Based on structural diversity and specific substituents |
Often limited to particular compounds |
Patent's breadth aims to block generic proliferation |
5. Implications for Stakeholders
5.1 For Pharmaceutical Innovators
- The patent's broad claims offered extensive protection during its lifetime.
- The expiry in 2017 exposed the market to generics.
- The landscape demonstrates the importance of broad genus claims coupled with early filing.
5.2 For Generic Manufacturers
- Post-2017, research into generic equivalents became feasible.
- Validity challenges or design-around strategies hinge on specific claims and prior art.
5.3 For Patent Owners (Historical)
- Enforceability during 1999-2017 provided Lilly exclusivity.
- The landscape underscores the importance of filing broad claims early in the development of chemical classes.
6. Deep Dive: Specific Claims and Structural Details
6.1 Sample Claims Breakdown
| Claim Number |
Type |
Summary |
Specific Elements |
| Claim 1 |
Compound |
A tetrahydrobenzazepine with specified substituents |
Core structure with defined R groups |
| Claim 7 |
Use |
Method of treating depression with claimed compounds |
Dosage, administration route unspecified |
| Claim 11 |
Process |
Synthetic route comprising certain intermediates |
Specific reagents and steps |
6.2 Structural Variations Covered
- Aromatic substitutions at R1, R2 positions, e.g., fluoro, methoxy groups.
- Side chains attached to the core structure for activity modulation.
- Heteroaryl replacements to improve pharmacokinetics.
7. Critical Success Factors and Limitations
| Factor |
Impact |
Notes |
| Broad genus claims |
Extended protection |
Difficult for competitors to design around |
| Specification detail |
Enabled primary rights |
Sufficient to support claim breadth |
| Patent expiry |
Market exposure |
Generic competition from 2017 onward |
| Prior art |
Narrowed scope |
Eli Lilly's early patents provided foundational priority |
8. Summary and Strategic Considerations
| Aspect |
Insights |
| Claim Breadth |
Encompasses a wide class of serotonin-active compounds, providing strong protection during patent lifetime. |
| Patent Strategy |
Filing broad genus claims early creates strong barriers; subsequent narrow patents reinforce position. |
| Post-Expiration Landscape |
Significant generic entry possible after 2017, reducing exclusivity. |
| Future Outlook |
Continuing innovation in chemical space and combination therapies remains key for maintaining competitive edge. |
Key Takeaways
- US 5,917,007 claims a broad chemical class of tetrahydrobenzazepine derivatives with therapeutic use in depression and related disorders.
- The patent’s structural and use claims provided robust protection during its active years (1999–2017).
- Expiry in 2017 opened the market to generics; subsequent patent landscape actions impact ongoing exclusivity.
- The patent exemplifies effective genus patenting, covering various substitution patterns to block competitors.
- Strategic patent filing and comprehensive claim coverage are critical for pharmaceutical innovators to secure market rights effectively.
5 FAQs About US Patent 5,917,007
1. What is the core chemical structure protected by US 5,917,007?
The patent covers substituted tetrahydrobenzazepine derivatives with customizable aromatic and heteroaryl substitutions, designed for serotonergic activity.
2. Does the patent include only chemical claims or therapeutic methods?
It encompasses both composition-of-matter claims and method-of-use claims for treating depression, anxiety, and related neurological disorders.
3. How does this patent relate to earlier antidepressant patents?
It builds on prior art such as Eli Lilly’s fluoxetine patent but expands the protected chemical space through genus claims, covering a wider array of related compounds.
4. When did the patent expire, and what are the implications?
Expired in 2017, allowing generic manufacturers to produce equivalents, thus increasing market competition.
5. Are there any ongoing patent protections related to this class?
While the patent itself expired, related patents, patent applications, or SPCs could provide limited or regional protection, requiring patent landscape analysis for each jurisdiction.
References
[1] US Patent 5,917,007. "Substituted 1,2,3,4-tetrahydrobenzazepine derivatives." Eli Lilly and Company, June 29, 1999.
[2] Patent landscape reports and literature on SSRIs and serotonergic agents.
[3] FDA ANDA filings and generic equivalent data post-2017.
[4] Patent life cycle and extension policies.
